

AVERTIS

AI-Powered Breast Screening:
Faster, Smarter, Better

IBP Selection Days - Health & Med Tech

Tuesday, 28th November 2023 @Online



+10%

Mortality risk with
1-month delay*



€103M

Annual extra
Healthcare Costs*


AVERTIS

Challenges in Early Detection

System Overloads



Increasing number
of women



Doctors shortage

Procedural Limitations



Complex analysis



Variability among
operators


AVERTIS

AVERTIS

AI-Powered Software-as-a-Service



Enhancing
Accuracy




Reducing
Delays




Improving
Patient Care

AVERTIS Innovative Technology




AVERTIS

AVERTIS Innovative Technology



AVERTIS

AVERTIS Target Market




AVERTIS

AVERTIS Customer segments



Public and Private
Hospitals



Research
Centres



Diagnostic
Centres



Manufacturers
of medical
devices



Lega Italiana
per la Lotta
contro i Tumori

801 centers focused on breast-related
medical activities

107*

AVERTIS

[5] <https://europadonna.it/ambito/breast-unit/monitoraggio/>

[6] <https://www.micuro.it/strutture?c=area-specialistica&g=8&id=68&s=¤tLatitude=45.478607384900364¤tLongitude=9.23222573148659>

[7] <https://www.lilt.it>

*approximately 1 per Italian province

AVERTIS Customer segments



Public and Private
Hospitals



Research
Centres



Diagnostic
Centres



Manufacturers
of medical
devices



Lega Italiana
per la Lotta
contro i Tumori

801 centers focused on breast-related
medical activities

107*

AVERTIS

[5] <https://europadonna.it/ambito/breast-unit/monitoraggio/>


[6] <https://www.micuro.it/strutture?c=area-specialistica&g=8&id=68&s=¤tLatitude=45.478607384900364¤tLongitude=9.23222573148659>

[7] <https://www.lilt.it>


*approximately 1 per Italian province

Competitive Scenario

Patient Data Integration



Competitive Advantage



Full Process Clinician Support

Patient History Integration for Personalized Analysis

Healthcare Systems Compatibility

Image database for Empowered Research

AVERTIS Team



Valentina Lidoni
CEO

MSc Student Biomedical Eng.
Healthcare & Innovation Analyst



Pablo Giaccaglia
CTO

MSc Student Computer Science Eng.



Leonardo Breda
Developer

MSc Student Mathematical Eng.

Affiliations



Marco D. Santambrogio
Scientific Advisor
Full Professor



Eleonora D'Arnese
Scientific Advisor
Postdoctoral Researcher

International experience



AVERTIS Ecosystem



Valentina Lidoni
CEO

MSc Student Biomedical Eng.
Healthcare & Innovation Analyst



Pablo Giaccaglia
CTO

MSc Student Computer Science Eng.



Leonardo Breda
Developer

MSc Student Mathematical Eng.



Marco D. Santambrogio
Scientific Advisor
Full Professor




Eleonora D'Arnese
Scientific Advisor
Postdoctoral Researcher




Alessandro S. Bertolini
Medical Advisor
Director of Medical Oncology Unit
Director of Oncology Department

Achievement to Date




AVERTIS

Project Roadmap



AVERTIS


Project Roadmap



AVERTIS

*Thank you for
your attention!*


AVERTIS



Contacts:
avertis.info@gmail.com

AVERTIS

ADDITIONAL MATERIAL



"Revolutionize breast cancer diagnosis through Artificial Intelligence"


We aim to harness AI for women's health, making diagnoses more accurate and timely, contributing to greater effectiveness in the fight against breast cancer.

"A world where every woman has access to highly accurate and timely breast cancer diagnoses, contributing to greater survival and well-being"



We aspire to create a future where breast cancer is detected early, treated successfully, and ultimately defeated.

- Accuracy
- Timeliness
- Customization
- Effective Communication
- Empowered Research

AVERTIS



AVERTIS Customer Journey Map



AVERTIS

External Analysis (1/2)

					
POLITICAL	ECONOMIC	SOCIAL	TECHNOLOGIC	ENVIRONMENTAL	LEGAL
<ul style="list-style-type: none">- Medical data privacy regulations- Government funding for breast cancer research<ul style="list-style-type: none">- Health regulations- Insurance coverage policies- Regional political stability- Startup and innovation laws	<ul style="list-style-type: none">- Global Economy<ul style="list-style-type: none">- Spending in Healthcare- Public vs. Private Relationship- Access to Credit and Financing- Exchange Rates- Taxes and Fiscal Regulations- Inflation	<ul style="list-style-type: none">- Awareness and Education- Acceptance of Technologies- Demographics and Geographic Distribution- Cultural and Social Aspects- Access to Health Care- Privacy and Data Security	<ul style="list-style-type: none">- Development of Diagnostic Technologies- Accessibility of Technologies- Systems Interoperability- Data Security- Technology Life Cycle- Training and Education	<ul style="list-style-type: none">- Environmental Sustainability- Environmental Regulations- Management of Natural Resources- Environmental Impact of Transportation<ul style="list-style-type: none">- Eco-friendly Technologies	<ul style="list-style-type: none">- Patient Privacy Regulations- Medical Device Safety Regulations- Intellectual Property Law- Contracting

P

E

S


T

E

L

AVERTIS

External Analysis (2/2)



AVERTIS


SWOT Analysis

Strengths

- Highly Innovative Solution
- Technological Autonomy
- Specialization and Customization
- Attention to Data
- Multidisciplinary Team
- Commitment to Innovation

Opportunities

- Growing Market
- Substantial Healthcare Investments
- Awareness and Social Acceptance
- Sustainability
- Strategic Collaborations



Weaknesses

- Dependence on External Suppliers
- Scarcity of Quality Data
- Need for Continuous Innovation
- Lengthy Certification Processes

Threats

- Stringent Regulations
- Economic Instability
- Competition and New Entrants
- Vertical Integration by Clients
- Complexity in Protecting Intellectual Property

AVERTIS



59% of Italian medical specialists

believe AI tools can help them
facilitate and improve their
professional activities


5-10% of healthcare spending

could be saved through
widespread AI adoption in the
next five years

AVERTIS



Go-to-market Strategy




AVERTIS

CE Marking Timeline and Costs

		Significance of Information provided by the MDSW to a healthcare situation related to diagnosis/therapy		
		High Treat or diagnose ~IMDRF 5.1.1	Medium Drives clinical management ~IMDRF 5.1.2	Low Informs clinical management (everything else)
State of Healthcare situation or patient condition	Critical situation or patient condition ~IMDRF 5.2.1	Class III <i>Category IV.i</i>	Class IIb <i>Category III.i</i>	Class IIa <i>Category II.i</i>
	Serious situation or patient condition ~IMDRF 5.2.2	Class IIb <i>Category III.ii</i>	Class IIa <i>Category II.ii</i>	Class IIa <i>Category I.ii</i>
	Non-serious situation or patient condition (everything else)	Class IIa <i>Category II.iii</i>	Class IIa <i>Category I.iii</i>	Class IIa <i>Category I.i</i>


Table 1: Classification Guidance on Rule 11

Technical Documentation & Quality Management System




AVERTIS

AVERTIS Innovative Technology



AVERTIS

AVERTIS MVP



AVERTIS